BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$70.24 USD
+1.22 (1.77%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $70.48 +0.24 (0.34%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
BMRN 70.24 +1.22(1.77%)
Will BMRN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMRN
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?
Other News for BMRN
BioMarin Pharmaceutical reaffirms long-term outlook
Wall Street Breakfast: The Week Ahead
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers
Biotech Alert: Searches spiking for these stocks today
BioMarin near-term impact from Ascendis data overblown, says Citi